CIP
UTHR icon

Chartwell Investment Partners’s United Therapeutics UTHR Stock Holding History

Chartwell Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,820
Closed -$2.87M – 434
2023
Q1 		$2.87M Buy
12,820
+2,101
+20% +$518K 0.11% 244
2022
Q4 		$2.98M Buy
10,719
+502
+5% +$127K 0.12% 233
2022
Q3 		$2.14M Buy
10,217
+3,183
+45% +$712K 0.09% 258
2022
Q2 		$1.66M Sell
7,034
-10,270
-59% -$2.09M 0.07% 295
2022
Q1 		$3.1M Sell
17,304
-21,978
-56% -$4.19M 0.1% 249
2021
Q4 		$8.49M Sell
39,282
-552
-1% -$108K 0.25% 151
2021
Q3 		$7.35M Buy
39,834
+12,715
+47% +$2.5M 0.23% 164
2021
Q2 		$4.87M Buy
27,119
+2,576
+10% +$491K 0.14% 210
2021
Q1 		$4.11M Sell
24,543
-943
-4% -$157K 0.12% 216
2020
Q4 		$3.87M Sell
25,486
-4,233
-14% -$555K 0.12% 221
2020
Q3 		$3M Buy
29,719
+411
+1% +$45.1K 0.11% 227
2020
Q2 		$3.55M Buy
+29,308
New +$3.3M 0.14% 210

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Chartwell Investment Partners's UTHR Position: Q2 2023 in Review

Chartwell Investment Partners sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 12,820 shares — an estimated $2.87M sold.

Chartwell Investment Partners first reported a position in UTHR in Q2 2020 and held it in 12 quarters. The position peaked at $8.49M in Q4 2021. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

  • Chartwell Investment Partners reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Chartwell Investment Partners sold 12,820 United Therapeutics shares in Q2 2023, an estimated $2.87M.
  • Chartwell Investment Partners first reported a position in United Therapeutics in Q2 2020 and held it in 12 quarters.
  • Chartwell Investment Partners's United Therapeutics position peaked at $8.49M in Q4 2021.
  • 473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Chartwell Investment Partners's 13F filing for Q2 2023, filed 25 Jul 2023.